An FHIT tumor suppressor gene?

Genes Chromosomes and Cancer

Volumn 21, Issue 4, 1998, Pages 281-289

  Le Beau, Michelle M ^a   Drabkin, Harry ^b   Glover, Thomas W ^c   Gemmill, Robert ^b   Rassool, Feyruz V ^a   McKeithan, Timothy W ^a   Smith, David I ^d  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIADENOSINE TETRAPHOSPHATE; DNA; HYDROLASE; TRINUCLEOTIDE;

BREAST CARCINOMA; CHROMOSOME 3P; CHROMOSOME BREAKAGE; CHROMOSOME FRAGILE SITE; DIGESTIVE SYSTEM TUMOR; GENE DELETION; HETEROZYGOSITY LOSS; HUMAN; KIDNEY TUMOR; NASOPHARYNX TUMOR; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY TRACT TUMOR; REVIEW; SCHIZOSACCHAROMYCES POMBE; TUMOR SUPPRESSOR GENE; UTERINE CERVIX TUMOR;

ACID ANHYDRIDE HYDROLASES; CHROMOSOME FRAGILE SITES; CHROMOSOME FRAGILITY; FRAGILE X SYNDROME; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASM PROTEINS; PROTEINS;

SCHIZOSACCHAROMYCES POMBE;

EID: 0031971241     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199804)21:4<281::AID-GCC1>3.0.CO;2-V     Document Type: Review

References (59)

1. Barnes LD, Garrison PN, Spirashvili Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M, Huebner K (1996) FHIT, a putative tumor suppressor in humans, is a dinucleoside 5',5' "-P1, P3-triphosphate hydrolase. Biochem 35:11529-11535.
2. Boldog F, Gemmill R, West J, Robinson M, Robinson L, Li E, Roche J. Todd S, Waggoner B, Lundstrom R, Jacobson J, Mullokandov MR, Klinger H, Drabkin HA (1997) Chromosome 3p l4 homozygous deletions and sequence analysis of FRA3B. Hum Mol Genet 6:193-203.
3. Brauch H, Johnson B, Hovis J, Yano T, Gazdar A, Pettengill OS, Graziano S, Sorenson GD, Poiesz BJ, Minna J, Linehan WM, Zbar B (1987) Molecular analysis of the short arm of chromosome 3 in small-cell and non-small-cell carcinoma of the lung. N Engl J Med 317:1109-1113.
4. Bugert P, Wilhelm M, Kovacs G (1997) FHIT gene and the FRA3B region are not involved in the genetics of renal cell carcinomas. Genes Chromosomes Cancer 20:9-15.
5. Coquclle A, Pipiras E, Toledo F, Buttin G, Debatisse M (1997) Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell 89:215-225.
6. Crossey PA. Richards KM, Foster K, Green JS, Prowse A, Latif F, Lerman MI, Zbar B, Affara N, Ferguson-Smith MA, Maher ER (1994) Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 3:1303-1308.
7. Devilee P, van den Brock M, Kuipers-Dijkshoorn N, Kolluri R, Khan PM, Pearson PL, Cornelisse CJ (1989) At least four different chromosomal regions are involved in loss of heterozygosity in human breast carcinoma, Genomics 5:554-560.
8. Druck T, Hadaczek P, Fu TB, Ohta M, Spirashvili Z, Baffa R, Negrini M, Kastury K, Veronese ML, Rosen D, Rothstein J, McCue P, Cotticelli MG, Inoue H, Croce CM, Huebner K (1997) Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 57:504-512.
9. Eppert K, Scherer SW, Ozcelik H, Pirone R, Hoodless P, Kim H. Tsui LC, Bapat B, Gallinger S, Andrulis IL, Thomsen GH, Wrana JL, Attisano L (1996) MADR2 maps to 18q21 and encodes a TGFβ-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 86:543-552.
10. Fazeli A, Dickinson SL, Hermiston ML, Tighe RV, Steen RG, Small CG, Stoeckli ET, Keino-Masu K, Masu M, Rayburn H, Simons J, Bronson RT, Gordon JI, Tessier-Lavigne M, Weinberg RA (1997) Phenotype of mice lacking functional Deleted in colorectal cancer (DCC) gene. Nature 386:796-804.
11. Fearon ER, Clio KR, Nigro JM, Kern SE, Simons JW, Ruppert JM, Hamilton SR, Preisinger AC, Thomas G, Kinzler KW, Vogelstein B (1990) Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247:49-56.
12. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido V, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, Giaccone G, Gazdar AF, Minna JD (1997) FHIT and FRA3B 3p l4.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 57:2256-2267.
13. Geurts JMW, Schoenmakers EFPM, Röijer E, Stenman G, Van de Yen WJM (1997) Expression of reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland. Cancer Res 57:13-17.
14. Glover TW, Stein CK (1987) Induction of sister chromatid exchanges at common fragile sites. Am J Hum Genet 41:882-890.
15. Glover TW, Stein CK (1988) Chromosome breakage and recombination at fragile sites. Am J Hum Genet 43:265-273.
16. Glover TW, Berger C, Coyle J, Echo B (1984) DNA polymerase alpha inhibition by aphidicolin induces gaps and breaks at common fragile sites in human chromosomes. Hum Genet 67:136-142.
17. Haber D, Harlow E (1997) Tumour-suppressor genes: Evolving definitions in the genomic age. Nat Genetics 16:320-322.
18. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350-353.
19. Jalal SM, Lindor NM, Michels VV, Buckley DD, Hoppe DA, Sarkar G, Dewald GW(1993) Absence of chromosome fragility at 19q13.3 in patients with myotonic dystrophy. Am J Med Genet 46:441-443.
20. Kastury K, Baffa R, Druck T, Ohta M, Cotticelli MG, Inoue H, Negrini M, Rugge M, Huang D, Croce CM, Palazzo J, Huebner K (1996) Potential gastrointestinal tumor suppressor locus at the 3p l4.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 56:978-983.
21. Kazmierczak B, Pohnke Y, Bullerdiek J (1996) Fusion transcripts between the HMGIC gene and RTVL-H-related sequences in mesenchymal tumors without cytogenetic aberrations. Genomics 38:223-226.
22. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton SR, Hedge P, Markham A, Carlson M. Joslyn G, Groden J, White R, Miki Y, Miyoshi Y, Nishisho I, Nakamura Y (1991) Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251:1366-1370.
23. Kok K, Osinga J, Carritt B, Davis MB, van der Hout AH, van der Veen AY, Landsvater RM, de Leij LF, Berendsen HH, Postmus PE, Poppema S, Buys CHCM (1987) Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 330:578-581.
24. Kovacs G, Erlandsson R, Boldog F, Ingvarsson S, Muller-Brechlin R, Klein G, Sumegi J (1988) Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci USA 85:1571-1575.
25. Kuo MT, Vyas RC, Jiang LX, Hittelman WN (1994) Chromosome breakage at a major fragile site associated with P-glycoprotein gene amplification in multidrug-resistant CHO cells. Mol Cell Biol 14:5202-5211.
26. Le Beau MM, Rowley JD (1984) Heritable fragile sites in cancer. Nature 308:607-608.
27. Leonardo KD, Hinck L, Masu M, Keino-Masu K, Ackerman SL, Tessier-Lavigne M (1997) Vertebrate homologues of C. elegans UNC-5 are candidate netrin receptors. Nature 386:833-838.
28. Lisitsyn NA, Lisitsina NM, Dalbagni G, Barker P, Sanchez, CA, Gnarra J, Linehan WM, Reid BJ, Wigler MH (1995) Comparative genomic analysis of tumors: Detection of DNA losses and amplification. Proc Natl Acad Sci USA 92:151-155.
29. Lo K-W, Tsao S-W, Huang DP, Lee JCK (1994) Detailed deletion mapping on the short arm of chromosome 3 in nasopharyngeal carcinomas. Int J Oncol 4:1359-1364.
30. Maestro R, Gasparotto D, Vukosavljevic T, Barzan L, Sulfano S, Boicchi M (1993) Three discrete regions of deletion at 3p in head and neck cancers. Cancer Res 53:5775-5779.
31. Matsumine A, Senda T, Baeg GH, Roy BC, Nakamura Y, Noda M, Toyoshima K, Akiyama T (1996) MCC, a cytoplasmic protein that blocks cell cycle progression from the G0/G1 to S phase. J Biol Chem 271:10341-10346.
32. Michael D, Beer DG, Wilke CM, Miller DE, Glover TW (1997) Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas. Oncugene, 15:1653-1659.
33. Naylor SL, Johnson BE, Minna JD, Sakaguchi AY (1987) Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 329:451-454.
34. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K, Croce CM (1996) The FHIT gene at 3p l4.2 is abnormal in breast carcinomas. Cancer Res 56:3173-3179.
35. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K (1996) The FHIT gene, spanning the chromosome 3p l4.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587-597.
36. Ong ST, Kong KM, Bader SA, Minna JD, Le Beau MM, McKeithan TW, Rassool FV (1997) Precise localization of the FHIT gene to the common fragile site at 3p l4.2 (FRA3B), and characterization of homozygous deletions within FRA3B that affect FHIT transcription in tumor cell lines. Genes Chromosomes Cancer 20:16-23.
37. Panagopoulos I, Thelin S, Mertens F, Mitelman F, Aman P (1997) Variable FHIT transcripts in non-neoplastic tissues. Genes Chromosomes Cancer 19:215-219.
38. Pandis N, Jin Y, Limon J, Bardi G, Idvall I, Mandahl N, Mitelman F, Heim S (1993) Interstitial deletion of the short arm of chromosome 3 as a primary chromosome abnormality in carcinomas of the breast. Genes Chromosomes Cancer 6:151-155.
39. Paradee W, Wilke CM, Hoge A, Glover TW, Smith DI (1996) A 350-kb cosmid contig in 3p l4.2 that crosses the t(3;8) hereditary renal cell carcinoma translocation breakpoint and 17 aphidicolininduced FRA3B breakpoints. Genomics 35:87-93.
40. Partridge M, Emilion G, Langdon JD (1996) LOH at 3p correlates with a poor survival in oral squamous cell carcinoma. Br J Cancer 73:366-371.
41. Plateau P, Blanquet S (1994) Dinucleoside oligophosphates in micro-organisms. Adv Microbiol Physiol 36:82-109.
42. Qian F, Watnick TJ, Onuchic LF, Germino GG (1996) The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell 87:979-987.
43. Rassool FV, McKeithan TW, Neilly ME, van Melle E, Espinosa III R, Le Beau MM (1991) Preferential integration of marker DNA into the chromosomal fragile site at 3p l4: An approach to cloning fragile sites. Proc Natl Acad Sci USA 88:6657-6661.
44. Rassool FV, Le Beau MM, Shen M-L, Neilly ME, Espinosa III R, Ong ST, Boldog F, Drabkin H, McCarroll R, McKeithan TW (1996) Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p l4.2. Genomics 35:109-117.
45. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, DeGregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K, Croce CM (1996) The FHIT gene at 3p l4.2 is abnormal in lung cancer. Cell 85:17-26.
46. Stadler WM, Olopade OI (1996) The 9p21 region in bladder cancer cell lines: Large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes. Urol Res 24:2.59-244.
47. Sutherland GR, Hecht F (1985) Fragile Sites on Human Chromosomes. Oxford: Oxford University Press.
48. Tamura G, Sakata K, Nishizuka S, Maesawa C, Suzuki V, Iwuya T, Terashima M, Saito K, Satodate R (1997) Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines. Genes Chromosomes Cancer 20:98-102.
49. Thiagalingam S, Lisitsyn NA, Hamaguehi M, Wigler MH, Willson JKV, Markowitz SD, Leach FS, Kinder KW, Vogelstein B (1996) Evaluation of the FHIT gene in colorectal cancers. Cancer Res 56:2936-2939.
50. Van den Berg A, Draaijers TG, Kok K, Timmer T, Van der Veen AY, Veldhuis PMJF, de Leij L, Gerhartz CD, Naylor SL, Smith DI, Buys CHCM (1997) Normal FHIT transcripts in renal cell cancer and lung cancer-derived cell lines, including a cell line with homozygous deletion in the KRA3R region. Genes Chromosomen Cancer 19:220-227.
51. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K, Croce CM (1996) FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 93:9770-9775.
52. Wang ND, Testa JR, Smith DI (1993) Determination of the specificity of aphidicolin-induced breakage of the human 3p l4.2 fragile site. Genomics 17:341-347.
53. Warren ST (1996) The expanding world of trinucleotide repeats. Science 271:1374-1375.
54. Wilke CM, Hall BK, Hoge A, Paradee W, Smith DI, Glover TW (1996) FRA3B extends over a broad region and contains a spontaneous HPV 16 integration site: Direct evidence for the coincidence of viral integration sites and fragile sites. Hum Mol Genet 5:187-195.
55. Wu CL, Sloan P, Read AP, Harris RH, Thakkwer NS (1994) Deletion mapping on the short arm of chromosome 3 in squamous cell carcinoma of the oral cavity. Cancer Res 54:6484-6488.
56. Yanagisawa K, Kondo M, Osada H, Uchida K, Takagi K, Masuda A, Takahashi T, Takahashi T (1996) Molecular analysis of the FHIT gene at 3p l4.2 in lung cancer cell lines. Cancer Res 56:5579-5582.
57. Vu S, Mangelsdorf M, Hewett D, Hobson L, Baker E, Eyre HJ, LapsysN, Le Paslier D, Doggett NA, Sutherland GR, Richards RI (1997) Human chromosomal fragile site FRA16B is un amplified AT-rich minisatellite repeat. Cell 88:367-374.
58. Yunis JJ, Soreng AL (1984) Constitutive fragile sites and cancer. Science 226:1199-1204.
59. Zbar B, Brauch H, Talmadge C, Linehan WM (1987) Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327:721-724.